Challenges in the Delivery of Peptide drugs: an Industry Perspective

References

• Shive M Anderson J . Biodegradation and biocompatibility of PLA and PLGA microspheres. Adv. Drug Deliv. Rev.28 (1), 5–24 (1997).
   PubMed Web of Science ®Google Scholar
• Hoffman AS . The origins and evolution of ‘controlled’ drug delivery systems. J. Control. Release132 (3), 153–163 (2008).
   PubMed Web of Science ®Google Scholar
• Klose D Siepmann F Elkharraz K Siepmann J . PLGA-based drug delivery systems: importance of the type of drug and device geometry. Int. J. Pharm.354 (1–2), 95–103 (2007).
   PubMedGoogle Scholar
• Tracy M.A Ward K.L Firouzabadian L Wang Y Dong N Qian R Zhang Y . Factors affecting the degradation rate of poly(lactide-co-glycolide) microspheres in vivo and in vitro. Biomaterials20 (11), 1057–1062 (1999).
   PubMed Web of Science ®Google Scholar
• Wischke C Schwendeman SP . Principles of encapsulating hydrophobic drugs in PLA/PLGA microparticles. Int. J. Pharm.364 (2), 298–327 (2008).
   PubMed Web of Science ®Google Scholar
• Kim HK Chung HJ Park TG . Biodegradable polymeric microspheres with ‘open/closed’ pores for sustained release of human growth hormone. J. Control. Release112 (2), 167–174 (2006).
   PubMed Web of Science ®Google Scholar
• Lewis AL Illum L . Formulation strategies for sustained release of proteins. Ther. Deliv.1 (3), 457–479 (2010).
   PubMedGoogle Scholar
• Jain RA . The manufacturing techniques of various drug loaded biodegradable poly(lactide-co-glycolide) (PLGA) devices. Biomaterials21 (23), 2475–2490 (2000).
   PubMed Web of Science ®Google Scholar
• Davies OR Lewis AL Whitaker MJ Tai H Shakesheff KM Howdle SM . Applications of supercritical CO2 in the fabrication of polymer systems for drug delivery and tissue engineering. Adv. Drug Deliv. Rev.60 (3), 373–387 (2008).
   PubMed Web of Science ®Google Scholar
• Kranz H Bodmeier R . Structure formation and characterization of injectable drug loaded biodegradable devices: in situ implants versus in situ microparticles. Eur. J. Pharm. Sci.34 (2–3), 164–172 (2008).
   PubMed Web of Science ®Google Scholar
• Luan X Bodmeier R . Modification of the tri-phasic drug release pattern of leuprolide acetate-loaded poly(lactide-co-glycolide) microparticles. Eur. J. Pharm. Biopharm.63 (2), 205–214 (2006).
   PubMed Web of Science ®Google Scholar
• European Commission REACH Legislation. http://ec.europa.eu/enterprise/sectors/chemicals/reach/index_en.htm.
   Google Scholar
• Siepmann J Faisant N Akiki J Richard J Benoit JP . Effect of the size of biodegradable microparticles on drug release: experiment and theory. J. Control. Release96 (1), 123–134 (2004).
   PubMed Web of Science ®Google Scholar
• Klose D Siepmann F Elkharraz K Krenzlin S Siepmann J . How porosity and size affect the drug release mechanisms from PLGA-based microparticles. Int. J. Pharm.314 (2), 198–206 (2006).
   PubMed Web of Science ®Google Scholar
• Faisant N Siepmann J Richard J Benoit J . Mathematical modeling of drug release from bioerodible microparticles: effect of gamma-irradiation. Eur. J. Pharm. Biopharm.56 (2), 271–279 (2003).
   PubMed Web of Science ®Google Scholar
• Vladisavljević GT Williams RA . Recent developments in manufacturing emulsions and particulate products using membranes. Adv. Colloid Interface Sci.113 (1), 1–20 (2005).
   PubMed Web of Science ®Google Scholar
• Joanicot M Ajdari A . Applied physics: droplet control for microfluidics. Science309 (5736), 887–888 (2005).
   PubMed Web of Science ®Google Scholar
• Björnmalm M Yan Y Caruso F . Engineering and evaluating drug delivery particles in microfluidic devices. J. Control. Release doi:10.1016/j.jconrel.2014.04.030 (2014) ( Epub ahead of print).
   PubMed Web of Science ®Google Scholar
• Bocanegra R José Luis Sampedro AG-C Marquez M . Monodisperse structured multi-vesicle microencapsulation using flow-focusing and controlled disturbance. J. Microencapsul.22 (7), 745–759 (2005).
   PubMed Web of Science ®Google Scholar
• Pérez C Castellanos IJ Costantino HR Al-Azzam W Griebenow K . Recent trends in stabilizing protein structure upon encapsulation and release from bioerodible polymers. J. Pharm. Pharmacol.54 (3), 301–313 (2002).
   PubMed Web of Science ®Google Scholar
• Hao J Whitaker MJ Wong B Serhatkulu G Shakesheff KM Howdle SM . Plasticization and spraying of poly (DL-lactic acid) using supercritical carbon dioxide: control of particle size. J. Pharm. Sci.93 (4), 1083–1090 (2004).
   PubMed Web of Science ®Google Scholar
• Whitaker MJ Hao J Davies OR et al. The production of protein-loaded microparticles by supercritical fluid enhanced mixing and spraying. J. Control Release101 (1–3), 85–92 (2005).
   PubMed Web of Science ®Google Scholar
• Jordan F Naylor A Kelly CA Howdle SM Lewis A Illum L . Sustained release hGH microsphere formulation produced by a novel supercritical fluid technology: in vivo studies. J. Control. Release141 (2), 153–160 (2010).
   PubMed Web of Science ®Google Scholar
• Pini R Storti G Mazzotti M Tai H Shakesheff KM Howdle SM . Sorption and swelling of poly (DL -lactic acid) and poly (lactic-co-glycolic acid) in supercritical CO2. Macromol. Symp.259 (1), 197–202 (2007).
   Google Scholar
• Chen Yulin Ping Ma Shuangying Gui . Cubic and hexagonal liquid crystals as drug delivery systems. Biomed Res. Int. doi: 10.1155/2014/815981 (2014) ( Epub ahead of print).
   Web of Science ®Google Scholar
• Norling Tomas Lading Pia Engström Sven Larsson Kåre Niels Krog SSN . Formulation of a drug delivery system based on a mixture of monoglycerides and triglycerides for use in the treatment of periodontal disease. J. Clin. Periodontol.19 (9), 687–692 (1992).
   PubMed Web of Science ®Google Scholar
• Ruiz-Hornillos J Henríquez-Santana A Moreno-Fernández A González IG Sánchez SR . Systemic allergic dermatitis caused by the solvent of Eligard. Contact Dermatitis61 (6), 355–356 (2009).
   PubMed Web of Science ®Google Scholar
• Asmus LR Tille J-C Kaufmann B et al. In vivo biocompatibility, sustained-release and stability of triptorelin formulations based on a liquid, degradable polymer. J. Control. Release165 (3), 199–206 (2013).
   PubMed Web of Science ®Google Scholar
• Heller J Barr J . Poly(ortho esters): from concept to reality. Biomacromolecules5 (5), 1625–1632 (2004).
   PubMed Web of Science ®Google Scholar
• Einmahl S Capancioni S Schwach-Abdellaoui K Moeller M Behar-Cohen F Gurny R . Therapeutic applications of viscous and injectable poly(ortho esters). Adv. Drug Deliv. Rev.53 (1), 45–73 (2001).
   PubMed Web of Science ®Google Scholar
• Heller J Barr J Ng SY Abdellauoi KS Gurny R . Poly(ortho esters): synthesis, characterization, properties and uses. Adv. Drug Deliv. Rev.54 (7), 1015–1039 (2002).
   PubMed Web of Science ®Google Scholar
• Heller J Barr J Ng SY et al. Poly(ortho esters): their development and some recent applications. Eur. J. Pharm. Biopharm.50 (1), 121–128 (2000).
   PubMed Web of Science ®Google Scholar
• Einmahl S Zignani M Varesio E et al. Concomitant and controlled release of dexamethasone and 5-fluorouracil from poly(ortho ester). Int. J. Pharm.185 (2), 189–198 (1999).
   PubMedGoogle Scholar
• Chan Y-P Meyrueix R Kravtzoff R Nicolas F Lundstrom K . Review on Medusa®: a polymer-based sustained release technology for protein and peptide drugs. Expert Opin. Drug Deliv.4 (4), 441–451 (2007).
   PubMed Web of Science ®Google Scholar
• Valéry C Paternostre M Robert B et al. Biomimetic organization: octapeptide self-assembly into nanotubes of viral capsid-like dimension. Proc. Natl. Acad. Sci. USA100 (18), 10258–10262 (2003).
   PubMed Web of Science ®Google Scholar
• Valéry C Artzner F Robert B et al. Self-association process of a peptide in solution: from beta-sheet filaments to large embedded nanotubes. Biophys. J.86 (4), 2484–2501 (2004).
   PubMed Web of Science ®Google Scholar
• Valéry C Pouget E Pandit A et al. Molecular origin of the self-assembly of lanreotide into nanotubes: a mutational approach. Biophys. J.94 (5), 1782–1795 (2008).
   PubMed Web of Science ®Google Scholar
• Pouget E Fay N Dujardin E et al. Elucidation of the self-assembly pathway of lanreotide octapeptide into beta-sheet nanotubes: role of two stable intermediates. J. Am. Chem. Soc.132 (12), 4230–4241 (2010).
   PubMed Web of Science ®Google Scholar
• Van Grondelle W Iglesias CL Coll E et al. Spontaneous fibrillation of the native neuropeptide hormone Somatostatin-14. J. Struct. Biol.160 (2), 211–223 (2007).
   PubMed Web of Science ®Google Scholar
• Maji SK Schubert D Rivier C Lee S Rivier JE Riek R . Amyloid as a depot for the formulation of long-acting drugs. PLoS Biol.6 (2), e17 (2008).
   PubMed Web of Science ®Google Scholar
• Reynolds Lucy McKee M . Serve the people or close the sale? Profit-driven overuse of injections and infusions in China's market-based healthcare system. Int. J. Health Plann. Manage.26 (4), 449–470 (2011).
   PubMed Web of Science ®Google Scholar
• Fransén N Bredenberg S Björk E . Clinical study shows improved absorption of desmopressin with novel formulation. Pharm. Res.26 (7), 1618–1625 (2009).
   PubMed Web of Science ®Google Scholar
• Brayden DJ Maher S . Oral absorption enhancement: taking the next steps in therapeutic delivery. Ther. Deliv.1 (1), 5–9 (2010).
   PubMedGoogle Scholar
• Welling SH Hubálek F Jacobsen J Brayden DJ Rahbek UL Buckley ST . The role of citric acid in oral peptide and protein formulations: relationship between calcium chelation and proteolysis inhibition. Eur. J. Pharm. Biopharm.86 (3), 544–551 (2014).
   PubMed Web of Science ®Google Scholar
• Rosenmayr-Templeton L . The oral delivery of peptides and proteins: established versus recently patented approaches. Pharm. Pat. Anal.2 (1), 125–145 (2013).
   PubMedGoogle Scholar
• Binkley N Bolognese M Sidorowicz-Bialynicka A et al. A Phase III trial of the efficacy and safety of oral recombinant calcitonin: the oral calcitonin in postmenopausal osteoporosis (ORACAL) trial. J. Bone Miner. Res.27 (8), 1821–1829 (2012).
   PubMed Web of Science ®Google Scholar
• Mehta N . Clinical development of an oral formulation of recombinant salmon calcitonin At : The Peptide Conference 2010.Cambridge, UK30–31 March, 2010.
   Google Scholar
• Henriksen K Andersen JR Riis BJ Mehta N Tavakkol R Alexandersen P Byrjalsen I Valter I Nedergaard BS Teglbjaerg CS Stern W Sturmer A Mitta S Nino AJ Fitzpatrick LA Christiansen CKM . Evaluation of the efficacy, safety and pharmacokinetic profile of oral recombinant human parathyroid hormone [rhPTH(1–31)NH(2)] in postmenopausal women with osteoporosis. Bone53 (1), 160–166 (2013).
   PubMed Web of Science ®Google Scholar
• Tuvia S Atsmon J Teichman SL et al. Oral octreotide absorption in human subjects: comparable pharmacokinetics to parenteral octreotide and effective growth hormone suppression. J. Clin. Endocrinol. Metab.97 (7), 2362–2369 (2012).
   PubMed Web of Science ®Google Scholar
• Tuvia S Salama P Weinstein I et al. OR14,80 OctreolinTM, a safe oral alternative for parenteral octreotide treatment. Growth Horm. IGF Res.20 (Suppl.1), S35–S36 (2010).
   Google Scholar
• Merrion Pharmacueticals . www.merrionpharma.com/content/investors/archive/2014/290514.asp.
   Google Scholar
• Business Standard . Biocon's oral insulin project expected to be delayed further.www.business-standard.com/article/companies/biocon-s-oral-insulin-project-expected-to-be-delayed-further-113122300378_1.html.
   Google Scholar
• Eldor R Arbit E Corcos A Kidron M . Glucose-reducing effect of the ORMD-0801 oral insulin preparation in patients with uncontrolled type 1 diabetes: a pilot study. PLoS ONE8 (4), e59524 (2013).
   PubMed Web of Science ®Google Scholar
• Related T Events A . The GTC Diabetes Summit. Oramed pharmaceuticals presents data from Phase IIA trial with ORMD-0801 in Type 2 diabetes. At : the 2014 Diabetes Summit. 2014, Cambridge Massachusetts, USAApril 24, 2014.
   Google Scholar
• Gutniak MK Larsson H Heiber SJ Juneskans OT Holst JJ Ahrén B . Potential therapeutic levels of glucagon-like peptide I achieved in humans by a buccal tablet. Diabetes Care19 (8), 843–848 (1996).
   PubMed Web of Science ®Google Scholar
• Gutniak MK Larsson H Sanders SW Juneskans O Holst JJ Ahrén B . GLP-1 tablet in Type 2 diabetes in fasting and postprandial conditions. Diabetes Care20 (12), 1874–1879 (1997).
   PubMed Web of Science ®Google Scholar
• Damme Van Oosterhuis-Kafeja F Van der Wielen M Almagor Y Sharon O Levin Y . Safety and efficacy of a novel microneedle device for dose sparing intradermal influenza vaccination in healthy adults. Vaccine14 (27), 454–459 (2009).
   Google Scholar
• Hafner R Couroux P Armstrong K Patel D Larche M Haumann B . Two year persistent treatment effect in reducing nasal symptoms of cat allergy after 4 doses of Cat-PAD, the first in a new class of synthetic peptide immuno-regulatory epitopes. Clin. Transl. Allergy3 (Suppl. 2), doi:10.1186/2045-7022-3-S2-O7 (2013).
   Google Scholar
• Radius Pharmaceuticals . Radius announces topline data from Phase II of BA058. http://radiuspharm.mwnewsroom.com/press-releases/radius-announces-positive-topline-data-from-phase–1080683.
   Google Scholar
• Zosano Pharmaceuticals . Zosano pharma, Inc., announces completes positive end-of-phase 2 meeting with FDA regarding zp- pth patch for osteoporosis. www.zosanopharma.com/index.php/Press-Release-12–19–2008.html.
   Google Scholar
• Daddona PE Matriano JA Mandema J Maa YF . Parathyroid hormone (1–34)-coated microneedle patch system: clinical pharmacokinetics and pharmacodynamics for treatment of osteoporosis. Pharm. Res.28 (1), 159–165 (2011).
   PubMed Web of Science ®Google Scholar
• Maggio ET . Intravail TM: highly effective intranasal delivery of peptide and protein drugs. Expert Opin. Drug Deliv.3 (4), 529–539 (2006).
   PubMedGoogle Scholar
• Eddy P Krause D Merutka G Macdonald B . Intranasal (IN) pharmacokinetics (PK) and bioavailability of ZT-031: a novel parathyroid hormone (PTH) analog. Presented at : ASBMR 30 Annual Meeting, 16 September 2009.
   Google Scholar
• Lewis AL Jordan F Illum L . CriticalSorbTM: enabling systemic delivery of macromolecules via the nasal route. Drug Deliv. Transl. Res.3 (1), 26–32 (2012).
   Web of Science ®Google Scholar
• Illum L . Nasal drug delivery: recent developments and future prospects. J. Control. Release161 (2), 254–263 (2012).
   PubMed Web of Science ®Google Scholar
• Bzik V Lewis A Illum L Brayden DJ . CriticalSorb promotes permeation of flux markers across rat colonic mucosae. Pharm. Res.29 (9), 2543–2554 (2012).
   PubMed Web of Science ®Google Scholar
• Critical Pharmaceuticals . Critical pharmaceuticals start dosing in Phase I on nasal PTH. www.criticalpharmaceuticals.com/latest/news/cp046-start-clinical.
   Google Scholar
• Hrkach J Von Hoff D Mukkaram Ali M et al. Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile. Sci. Transl. Med.4 (128), 128–139 (2012).
   Web of Science ®Google Scholar
• Gaillard PJ Appeldoorn CCM Dorland R et al. Pharmacokinetics, brain delivery, and efficacy in brain tumor-bearing mice of glutathione pegylated liposomal doxorubicin (2B3–101). PLoS ONE9 (1), e82331 (2014).
   PubMed Web of Science ®Google Scholar